Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide

Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment

(2016) Frank Bridoux et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study

(2016) Michinori Ogura et al.   Lancet Haematology

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

(2015) R. S. Komrokji et al.   ANNALS OF ONCOLOGY

Inflammation rapidly reorganizes mouse bone marrow B cells and their environment in conjunction with early IgM responses

(2015) J. M. Moreau et al.   BLOOD

Evaluation of Pharmacokinetic and Pharmacodynamic Interactions when Lenalidomide is Co-administered with Warfarin in a Randomized Clinical Trial Setting

(2015) Daniel Weiss et al.   CLINICAL DRUG INVESTIGATION

Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children

(2015) Frederique Rodieux et al.   CLINICAL PHARMACOKINETICS

Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond

(2015) Andrew A Guirguis et al.   CURRENT OPINION IN CELL BIOLOGY

An update on the use of lenalidomide for the treatment of multiple myeloma

(2015) Flora Zagouri et al.   EXPERT OPINION ON PHARMACOTHERAPY

Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma

(2015) M. A. Dimopoulos et al.   HAEMATOLOGICA

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma

(2015) M. A. Dimopoulos et al.   HAEMATOLOGICA

Expanding role of lenalidomide in hematologic malignancies

(2015) Nilanjan Ghosh et al.   Cancer Management and Research

Stability of lenalidomide suspension after preparation by a simple suspension method for enteral tube administration

(2015) Tomoko O Morita et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Erratum to: No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers

(2014) Nianhang Chen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug–drug interactions

(2014) Zeen Tong et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

(2014) Lotfi Benboubker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide at Therapeutic and Supratherapeutic Doses Does Not Prolong QTc Intervals in the Thorough QTc Study Conducted in Healthy Men

(2013) Nianhang Chen et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Cerebrospinal fluid penetrance of lenalidomide in meningeal myeloma

(2013) Saiyed Anwer et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN

(2013) Anita K. Gandhi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study

(2013) Andre Goy et al.   JOURNAL OF CLINICAL ONCOLOGY

A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial

(2013) Jian Hou et al.   Journal of Hematology & Oncology

Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome

(2012) R. S. Komrokji et al.   BLOOD

Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity

(2012) N. Chen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Interleukin-10 spot-forming cells as a novel biomarker of chronic graft-versus-host disease

(2012) M. Hirayama et al.   HAEMATOLOGICA

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

(2012) A Lopez-Girona et al.   LEUKEMIA

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma

(2012) Yuan Xiao Zhu et al.   LEUKEMIA & LYMPHOMA

Lenalidomide-induced elevated bilirubin

(2012) Katherine A Simondsen et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Drug interaction between lenalidomide and itraconazole

(2011) Naoto Takahashi et al.   AMERICAN JOURNAL OF HEMATOLOGY

A review of the history, properties, and use of the immunomodulatory compound lenalidomide

(2011) Jerome B. Zeldis et al.   Annals of the New York Academy of Sciences

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

(2011) P. Fenaux et al.   BLOOD

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

(2011) Y. X. Zhu et al.   BLOOD

Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects

(2011) Nianhang Chen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide–CCI-779 Interaction via P-Glycoprotein

(2011) Craig C. Hofmeister et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiple Myeloma, Venous Thromboembolism, and Treatment-Related Risk of Thrombosis

(2011) Elena Zamagni et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment

(2010) Ulrike Klein et al.   ANNALS OF HEMATOLOGY

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes

(2010) Carla Heise et al.   Expert Review of Anticancer Therapy

Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma

(2010) Shinsuke Iida et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias

(2010) William Blum et al.   JOURNAL OF CLINICAL ONCOLOGY

Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group

(2010) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of Lenalidomide in Pediatric Patients With Recurrent, Refractory, or Progressive Primary CNS Tumors: Pediatric Brain Tumor Consortium Study PBTC-018

(2010) Katherine E. Warren et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report

(2010) Stacey L. Berg et al.   JOURNAL OF CLINICAL ONCOLOGY

Distribution of Lenalidomide Into Semen of Healthy Men After Multiple Oral Doses

(2010) Nianhang Chen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality

(2009) Hironori Harada et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer

(2009) William L. Dahut et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction

(2008) Gondi Kumar et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Drug–Drug Interactions Mediated Through P-Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe Drug

(2008) KS Fenner et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Warfarin therapy: in need of improvement after all these years

(2008) Stephen E Kimmel   EXPERT OPINION ON PHARMACOTHERAPY